The scale of the problem provides the urgency. Gastric cancer alone affects more than one million people each year and accounts for roughly 5.7 percent of all cancers worldwide, yet a large proportion of patients are diagnosed only at advanced stages, when survival prospects are grim. Helicobacter pylori remains the best-established infectious risk factor, but it is no longer viewed as the sole microbial culprit. Chronic mucosal inflammation triggered by a dysbiotic community can reshape the gastric environment, and repeated activation of the host immune system by gut bacteria creates a persistent inflammatory state in which normally benign residents, so-called pathobionts, can cooperate with dietary and environmental carcinogens to push cells toward malignancy. Worryingly, studies show that cancerous tissues in the digestive tract harbor more diverse and abundant microbial populations than adjacent stromal tissue, and that microbial diversity is higher in advanced gastric cancer than in early disease.

The oral cavity has emerged as a surprising reservoir of cancer-associated organisms. Housing roughly 500 to 700 bacterial species distributed across distinct niches such as saliva, dental plaque, and the tongue, the mouth hosts microbes that appear linked to cancers far downstream. Porphyromonas gingivalis, a notorious periodontal pathogen, makes oral cancer cells more aggressive and resistant to chemotherapy by stimulating Toll-like receptor 4 and myeloid differentiation factor 88, activating the nuclear factor-κB pathway and releasing pro-inflammatory cytokines. Its lipopolysaccharide also appears to promote pancreatic cancer through MyD88-dependent signaling that biases dendritic cells toward T helper 2 differentiation. Meanwhile, molecular surveys using 16S rRNA gene sequencing have detected oral species such as Parvimonas micra, Streptococcus anginosus, Slackia exigua, and Peptostreptococcus stomatis within gastric tumors, likely because a reduction in gastric acidity, sometimes exacerbated by proton pump inhibitors, opens a colonization window for microbes that would otherwise be destroyed.

In the colon, the densest microbial reservoir in the human body, specific organisms have been interrogated at the mechanistic level. Fusobacterium nucleatum, a commensal of the mouth, uses its FadA adhesin to trigger transcriptional changes in colorectal cancer cells and drives proliferation and migration through the TLR4/MyD88/NF-κB axis, including modulation of the microRNA miR-21. Enterotoxigenic Bacteroides fragilis promotes intestinal tumorigenesis in mouse models via inflammatory STAT3 and T helper 17 mechanisms. Peptostreptococcus anaerobes, found at higher abundance in the stool of colorectal cancer patients, bind α2/β1 integrins through a surface protein, activating focal adhesion kinase phosphorylation and the PI3K/AKT pathway, which fuels cell proliferation and inflammation. Other bacteria are genotoxic in a more direct sense: certain Escherichia coli strains produce colibactin, while H. pylori strains carrying the cytotoxin-associated gene A deliver a virulence factor that manipulates host signaling, and both belong to a class of toxins called cyclomodulins that disrupt the cell cycle and render their producers highly carcinogenic.

What unifies these observations is the recognition that dysbiosis-driven carcinogenesis is not the product of a single pathway but a networked collapse of multiple regulatory systems. Bacterial metabolites, altered bile acid metabolism, weakening of the mucosal barrier, and activation of signaling cascades such as NF-κB, STAT3, and Wnt/β-catenin act in concert to create a tumor-permissive microenvironment. Microbial products also include reactive oxygen species, reactive nitrogen species, hydrogen sulfide, nitrosamines, and acetaldehyde, all of which inflict genotoxic stress on epithelial cells. Crucially, the gut microbiota also metabolizes environmental chemicals and food compounds, either detoxifying them or converting them into more dangerous intermediates, which means that the functional activity of the community, not merely its taxonomic composition, determines cancer risk. This functional perspective is reshaping how researchers design microbiome studies.

Nowhere is the mechanistic detail richer than in H. pylori-driven gastric cancer. The bacterium sustains STAT3 activation by upregulating interleukin 6, by shuttling CagA into epithelial cells where it acts through the SHP-2 pathway, and by engaging TLR2 to amplify inflammatory responses. Recent work shows H. pylori drives overexpression of DAB2 through the SRC-YAP1 axis in a STAT3-dependent manner, and activates fibroblast growth factor receptor 4 via STAT3, both processes linked to carcinogenesis. On the NF-κB front, CagA directly stimulates the transcription factor and increases its nuclear shuttling, while the bacterium activates the IκB kinase complex to boost production of tumor necrosis factor-α and interleukin 1β. One study traced an NF-κB-driven PIEZO1/YAP1/CTGF pathway through which H. pylori remodels the gastric tumor microenvironment. The Wnt/β-catenin pathway is similarly hijacked: CagA promotes the accumulation and nuclear translocation of β-catenin, H. pylori-induced LRP8 expression facilitates that nuclear entry, and the resulting expression of epithelial-to-mesenchymal transition transcription factors confers stem-like properties and invasive behavior on tumor cells. The bacterium also modulates the three major MAPK branches, JNK, ERK, and p38, and selectively downregulates other JAK-STAT components as an immune-evasion strategy.

Barrier failure adds another layer of vulnerability. The intestinal mucosal barrier, composed of epithelial cells, tight junctions, the mucus layer, and the mucosal immune system, normally keeps microbial products out of the circulation. Dysbiosis, particularly in aging, reduces microbial diversity, weakens intercellular junctions, and increases epithelial permeability, producing a leaky gut through which lipopolysaccharides and peptidoglycans flood the lamina propria and bloodstream. There they engage pattern recognition receptors and trigger chronic systemic inflammation, oxidative stress, and DNA damage, conditions that favor tumor initiation, progression, and metastasis. Barrier dysfunction also impairs antitumor immunity and can blunt the efficacy of anticancer therapies, especially immunotherapy, making the restoration of barrier integrity and microbial balance an emerging therapeutic strategy.

Even blood, long considered sterile, may carry diagnostic echoes of the gut. Culture-independent sequencing has detected microbial DNA in blood, although the existence of a stable blood-resident microbiome remains controversial because low biomass makes contamination a serious methodological concern. Nonetheless, several studies report that the blood microbiome of gastric cancer patients differs significantly from that of healthy individuals, with elevated levels of Bacteroides, Haemophilus parainfluenzae, and Acinetobacter, and that serum microbial profiles correlate with tumor size, invasion depth, metastasis, and even the distinction between lymphatic and non-lymphatic spread. In advanced colorectal cancer, patients who responded to immunochemotherapy combined with adoptive T-cell therapy carried higher concentrations of Bifidobacterium, Lactobacillus, and Enterococcus in their blood than non-responders, hinting that microbial signatures might predict treatment outcomes.

The biomarker potential extends across the digestive tract. In the esophagus, a shift from a predominantly streptococcal community toward one enriched with Actinomyces, Veillonella, Neisseria, Fusobacterium, and Porphyromonas marks an unhealthy state, and several-fold increases in Clostridiales species, F. nucleatum, Erysipelotrichales, or P. gingivalis have been proposed as prognostic indicators for esophageal squamous cell carcinoma. Gastric cancer patients show high levels of Lactobacillus, Lactococcus, and the Lachnospiraceae family alongside oral taxa such as Haemophilus and Campylobacter, and distinct subtype-specific signatures have been reported, with Proteobacteria and Acidobacteria dominating adenocarcinomas while Fusobacteria and Bacteroidetes prevail in signet ring cell carcinomas. In saliva, pancreatic cancer patients show reduced Streptococcus mitis and Neisseria elongata and an elevated Leptotrichia-to-Porphyromonas ratio, while F. nucleatum in stool is being explored as a noninvasive early-detection marker for colorectal cancer.

The authors are careful to note that the evidence is not yet ready for the clinic. Individual differences in diet, medication use, geography, sampling methods, and sequencing protocols confound current findings, and no microbial marker has been validated for routine clinical application. What the field needs, they argue, are longitudinal and multicenter studies with standardized sampling and multiomic approaches that independently validate microbial markers, alone and in combination. If that work succeeds, a detailed understanding of the interplay between the microbiome, epithelial cells, the immune system, and the tumor microenvironment could yield new targets for prevention, earlier detection, and treatment of gastrointestinal cancers, transforming the trillions of microbes we carry from an invisible background into a usable map of risk. For now, the message is clear: the balance of our inner ecosystem may be one of the most consequential frontiers in cancer medicine.

Subject of Research: The role of gastrointestinal microbiome dysbiosis in digestive cancer development and biomarker potential

Article Title: Gastrointestinal Microbiome Dysbiosis in Cancer Development: Mechanisms and Biomarker Potential

Article References: Gastrointestinal Microbiome Dysbiosis in Cancer Development: Mechanisms and Biomarker Potential. (n.d.). https://doi.org/10.1002/mbo3.70404

Image Credits: AI Generated

DOI: 10.1002/mbo3.70404

Keywords: microbiome, dysbiosis, gastric cancer, colorectal cancer, Helicobacter pylori, Fusobacterium nucleatum, NF-κB, biomarkers, microbial translocation, gut barrier, oral microbiome, cancer immunotherapy